Your browser is no longer supported. Please, upgrade your browser.
Settings
ALBO Albireo Pharma, Inc. daily Stock Chart
ALBO [NASD]
Albireo Pharma, Inc.
Index- P/E- EPS (ttm)-10.91 Insider Own22.10% Shs Outstand8.84M Perf Week-4.02%
Market Cap206.94M Forward P/E- EPS next Y-3.13 Insider Trans-20.38% Shs Float6.93M Perf Month-14.87%
Income-25.20M PEG- EPS next Q-0.80 Inst Own49.60% Short Float0.62% Perf Quarter0.47%
Sales11.40M P/S18.15 EPS this Y-104.60% Inst Trans4.50% Short Ratio1.15 Perf Half Y22.44%
Book/sh7.78 P/B3.01 EPS next Y8.50% ROA- Target Price62.00 Perf Year-5.45%
Cash/sh6.46 P/C3.62 EPS next 5Y- ROE- 52W Range15.31 - 29.20 Perf YTD32.04%
Dividend- P/FCF- EPS past 5Y25.40% ROI-30.80% 52W High-19.83% Beta1.42
Dividend %- Quick Ratio7.30 Sales past 5Y- Gross Margin- 52W Low52.91% ATR1.62
Employees13 Current Ratio7.30 Sales Q/Q- Oper. Margin- RSI (14)40.51 Volatility6.99% 7.18%
OptionableNo Debt/Eq0.02 EPS Q/Q0.60% Profit Margin- Rel Volume1.06 Prev Close24.91
ShortableYes LT Debt/Eq0.00 EarningsNov 20 BMO Payout- Avg Volume37.52K Price23.41
Recom1.50 SMA20-7.69% SMA50-7.65% SMA2000.77% Volume39,204 Change-6.02%
Nov-15-17Initiated ROTH Capital Buy $92
Jul-18-17Initiated Needham Buy $35
Jun-30-17Initiated Wedbush Outperform $58
Feb-16-17Initiated Ladenburg Thalmann Buy $40
Dec-05-17 05:02PM  [$$] AstraZeneca Sells $10.7 Million in Albireo Stock Barrons.com
Nov-14-17 08:00AM  Albireo Reports Third Quarter 2017 Financial Results GlobeNewswire -10.73%
Nov-09-17 08:00AM  Albireo to Present at the Jefferies 2017 London Healthcare Conference GlobeNewswire
Oct-24-17 07:30AM  Featured Company News - Albireo Pharma to Present Final Results of Phase-2 Study of A4250 in Children with Cholestatic Liver Disease at The Liver Meeting(R) 2017 ACCESSWIRE
Oct-20-17 08:00AM  Final Results of Albireos Phase 2 Study of A4250 in Children with Cholestatic Liver Disease Presented at The Liver Meeting® 2017 GlobeNewswire
Oct-16-17 08:00AM  Albireo to Host KOL Event on Progressive Familial Intrahepatic Cholestasis GlobeNewswire
Oct-03-17 08:00AM  Final Results of Albireos Phase 2 Study of A4250 in Children with Cholestatic Liver Disease to be Presented at The Liver Meeting® 2017 GlobeNewswire
Sep-28-17 08:00AM  Albireo Elects Roger Jeffs to Board of Directors GlobeNewswire
Sep-26-17 08:00AM  EMAs Paediatric Committee Agrees to Albireos A4250 Pediatric Investigation Plan GlobeNewswire -6.38%
Sep-19-17 08:24AM  Albireo to Present at Investor Conferences in September GlobeNewswire
07:10AM  Featured Company News - RXi Pharma's Chief Business Officer, Alexey Eliseev, to Leave the Company ACCESSWIRE
Sep-05-17 08:00AM  Albireo to Present at 19th Annual Rodman & Renshaw Global Investment Conference GlobeNewswire -11.10%
Aug-21-17 08:36AM  Albireo Reports Second Quarter 2017 Financial Results GlobeNewswire
Aug-08-17 08:00AM  Albireo to Present at Wedbush PacGrow Healthcare Conference GlobeNewswire
May-30-17 04:01PM  Albireo Announces Closing of $51.9 Million Public Offering Including Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire +14.00%
May-24-17 08:39AM  Albireo Prices $45.1 Million Public Offering of Common Stock GlobeNewswire
May-23-17 04:01PM  Albireo Announces Proposed Public Offering of Common Stock GlobeNewswire
May-18-17 08:00AM  Albireo Announces Plans for Phase 3 Clinical Program of A4250 in Patients with PFIC GlobeNewswire
May-16-17 08:00AM  Albireo Announces Two New U.S. Patents Allowed for A4250 with Term into 2031 GlobeNewswire
May-10-17 04:01PM  Albireo Reports First Quarter 2017 Financial Results GlobeNewswire
Apr-27-17 08:00AM  Albireo Announces Elobixibat Data from Japan to be Presented at DDW 2017 GlobeNewswire
Apr-22-17 01:00AM  Promising Pediatric Data for Albireos A4250 to be Presented at The International Liver Congress 2017 GlobeNewswire
Apr-10-17 08:00AM  Albireo to Host KOL Meeting on Rare Pediatric Liver Diseases on April 12 GlobeNewswire
Apr-05-17 08:00AM  EASL Selects Albireos A4250 Data for Late Breaker Presentation GlobeNewswire
08:00AM  EASL Selects Albireos A4250 Data for Late Breaker Presentation
Mar-31-17 01:04PM  ALBIREO PHARMA, INC. Financials
Mar-28-17 08:00AM  Albireo to Present at Upcoming Investor Conferences GlobeNewswire
Mar-14-17 07:36AM  ALBIREO PHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi -6.71%
07:30AM  Albireo Reports 2016 Financial Results GlobeNewswire
Mar-07-17 08:00AM  Albireo to Host Conference Call and Webcast on March 14 at 8:30 a.m. ET to Discuss Year-End 2016 Financial Results and Operational Highlights GlobeNewswire
Mar-01-17 08:00AM  Albireo to Present at 37th Annual Cowen and Company Health Care Conference GlobeNewswire
Feb-16-17 07:00AM  Coverage initiated on Albireo Pharma by Ladenburg Thalmann +11.39%
Feb-10-17 04:33PM  ALBIREO PHARMA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial O
Feb-06-17 08:00AM  Albireo to Present at 19th Annual BIO CEO & Investor Conference GlobeNewswire
Feb-01-17 08:00AM  Albireo Announces Submission of New Drug Application for Elobixibat in Japan GlobeNewswire
Jan-27-17 05:01PM  ALBIREO PHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Dec-30-16 01:04PM  ALBIREO PHARMA, INC. Financials
Dec-22-16 04:06PM  ALBIREO PHARMA, INC. Files SEC form 8-K/A, Financial Statements and Exhibits +8.18%
04:03PM  ALBIREO PHARMA, INC. Files SEC form 10-K, Annual Report
Dec-21-16 05:10PM  ALBIREO PHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits -7.33%
Dec-16-16 04:32PM  ALBIREO PHARMA, INC. Files SEC form 8-K/A, Financial Statements and Exhibits -5.45%
Nov-29-16 08:00AM  Albireo Expands Team, Appoints Martha J. Carter as Chief Regulatory Officer GlobeNewswire
Nov-16-16 04:50PM  LifeSci Capital Initiates Coverage of Albireo Accesswire
Nov-15-16 09:01AM  Albireos Lead Product Candidate for Orphan Pediatric Liver Disease Accepted Into European Medicines Agencys PRIME Program GlobeNewswire +12.54%
Nov-04-16 05:09PM  ALBIREO PHARMA, INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Creation of a Direct Fin -24.99%
Albireo Pharma Inc is biopharmaceutical company. It is engaged in developing & commercializing novel bile acid modulators to treat orphan pediatric liver diseases & gastrointestinal disorders.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ASTRAZENECA PLC10% OwnerDec 01Sale21.40500,00010,700,000508,141Dec 05 04:18 PM